BetterLife Pharma

Vancouver-based BetterLife Pharma is a biotechnology company founded in 2002 that entered the psychedelic space by acquiring Transcend Biodynamics in December 2020. The company now develops and commercializes novel psychedelics (second-generation non-hallucinogenic compounds) and antiviral products for neuropsychiatric disorders and early-stage Covid-19. 

The company's primary focus is on two compounds: BETR-001 and BETR-002. BETR-001 is a non-hallucinogenic and non-controlled LSD derivative in preclinical and IND-enabling studies. It is unregulated and can potentially be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles, and its pending patent covers the treatment of major depressive disorder, anxiety disorder, neuropathic pain, and other neuro-psychiatric and neurological disorders. BETR-002, also in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. The company has a pending method of use and formulations patent for BETR-002 covering the treatment of anxiety-related disorders, including benzodiazepine dependence.

BetterLife is also exploring the substances to treat other neuropsychiatric disorders as well. Additionally, the company is in the process of advancing its patent-pending nebulizer treatment targeting early-stage Covid-19. The company is also developing a liposomal delivery platform through its fully owned subsidiary Altum Pharmaceuticals called the BiPhasix.

BetterLife is listed on the Canadian Securities Exchange (CSE) under the ticker symbol “BETR” and the over-the-counter (OTC) markets under the ticker symbol “BETRF.”